2011 sales: $823 million (estimated)
Maker: Medtronic ($MDT)
Back story: The Minnesota device giant has produced many iterations of its Endeavor/Resolute drug-eluting stents (the names have even overlapped in the past). In doing so, it grabbed market share in a highly competitive sector whose total size is in decline, hitting the No. 2 selling spot. Endeavor/Resolute sales had declined from $762 million in estimated sales in 2009 to $725 million in 2010, so the jump to $823 million last year is especially worth noting. Today, the company is banking on its Resolute Integrity stent, its latest-generation version that stands out because it is made from a single strand of wire, making it easier to deliver and function. Medtronic is also boosting sales by pursuing as many approved uses as possible for the stent; it is the only one of its kind FDA-approved for diabetic patients, for example. Earlier this year, it also gained a CE mark in Europe for 7 new indications, plus approval in Japan. A note: Medtronic doesn't provide sales for its drug-eluting stents, so EvaluateMedTech collected the sales figures from analyst reports, which count Endeavor and Resolute together at the segmental sales level rather than the product sales level.
Medtronic's Resolute Integrity stent gains CE mark for 7 new indications
FDA panel: Approve Medtronic stent
Stent sales stabilize as rival enters
Japan may be key to further propelling Resolute stent sales